#AngioDynamics

Fundamental analysis of $ANGO (ANGIODYNAMICS INC) based on financial data and reported results.

#ANGO #ANGIODYNAMICS

AngioDynamics Shares Slip After Canaccord Cuts Target Canaccord cut AngioDynamics' 12-month target on Apr 6, 2026, citing margin pressure; intraday moves were ~3–7% and trading volume rose (source: Investing.com).

AngioDynamics Shares Slip After Canaccord Cuts Target: Canaccord cut AngioDynamics' 12-month target on Apr 6, 2026, citing margin pressure; intraday moves were ~3–7% and trading volume rose (source: Investing.com). 👈 Read full analysis #AngioDynamics #Canaccord #StockMarket #Investing #FinancialNews

AngioDynamics Q3 2026 Results Show Revenue Miss AngioDynamics reported $117.3M in Q3 2026 revenue (Apr 2, 2026), down 3.4% YoY; adjusted EPS $0.18 and guidance narrowed to $465–475M for FY2026.

AngioDynamics Q3 2026 Results Show Revenue Miss: AngioDynamics reported $117.3M in Q3 2026 revenue (Apr 2, 2026), down 3.4% YoY; adjusted EPS $0.18 and guidance narrowed to $465–475M for FY2026. 👈 Read full analysis #AngioDynamics #QuarterlyResults #EarningsReport #Healthcare #MedicalDevices

AngioDynamics Shares Slip After Canaccord Lowers Target On Apr 2, 2026 Canaccord cut AngioDynamics' price target after management lowered 2026 EBITDA guidance, per Investing.com; investors must now reprice near-term profitability risks.

AngioDynamics Shares Slip After Canaccord Lowers Target: On Apr 2, 2026 Canaccord cut AngioDynamics' price target after management lowered 2026 EBITDA guidance, per Investing.com; investors must now reprice near-term… 👈 Read full analysis #AngioDynamics #Investing #FinanceNews #StockMarket #EBITDA

AngioDynamics Q1 Revenue $78.42M, Non-GAAP EPS -$0.07 AngioDynamics reported Q1 2026 non-GAAP EPS of -$0.07 and revenue of $78.42M on Apr 2, 2026, beating EPS by $0.04 and revenue by $1.65M.

AngioDynamics Q1 Revenue $78.42M, Non-GAAP EPS -$0.07: AngioDynamics reported Q1 2026 non-GAAP EPS of -$0.07 and revenue of $78.42M on Apr 2, 2026, beating EPS by $0.04 and revenue by $1.65M. 👈 Read full analysis #AngioDynamics #RevenueGrowth #Q1Results #FinancialReport #Investing